INVVY - Indivior PLC

Other OTC - Other OTC Delayed Price. Currency in USD
3.4950
+0.2450 (+7.54%)
At close: 12:22PM EDT
Stock chart is not supported by your current browser
Previous Close3.2500
Open3.4500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range3.4500 - 3.4950
52 Week Range1.9750 - 14.3300
Volume4,279
Avg. Volume12,475
Market Cap509.508M
Beta (3Y Monthly)-0.73
PE Ratio (TTM)2.06
EPS (TTM)1.7000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2016-06-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Financial Times

    Indivior shares rise as it boosts guidance for a second time

    London-listed drugmaker Indivior has raised its guidance for this year’s earnings for a second time following the strong performance of a drug used to treat opioid addiction, sending shares 10 per cent higher in early trading. Indivior said the primary driver of the raised guidance was the outperformance of Suboxone, which is used in the treatment of patients seeking to beat opioid addiction and has been facing competition from cheaper “generic” alternatives.

  • PR Newswire

    Announcement of National Institutes of Health (NIH) Grant Award through the NIH Helping to End Addiction Long-term (HEAL) Initiative

    RICHMOND, Va., Sept. 26, 2019 /PRNewswire/ -- Indivior PLC (INDV.L) announces that the National Institutes of Health (NIH) has granted Indivior's application entitled  "Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder" pursuant to Funding Opportunity Announcement RFA-DA-19-002 dedicated to the development of medications to prevent and treat opioid use disorder and overdose. Indivior's award is one of 375 grant awards across 41 states made by the NIH in fiscal year 2019 to apply scientific solutions to reverse the national opioid crisis.

  • These 4 Measures Indicate That Indivior (LON:INDV) Is Using Debt Safely
    Simply Wall St.

    These 4 Measures Indicate That Indivior (LON:INDV) Is Using Debt Safely

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • Should Value Investors Consider Indivior (INVVY) Stock Now?
    Zacks

    Should Value Investors Consider Indivior (INVVY) Stock Now?

    Let's see if Indivior (INVVY) stock is a good choice for value-oriented investors right now from multiple angles.

  • Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?
    Zacks

    Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?

    Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Reuters

    UPDATE 1-Indivior profit rises on slower-than-expected Suboxone market share loss

    Drugmaker Indivior Plc reported a 14% rise in quarterly profit on Wednesday, as its best-selling opioid addiction drug Suboxone lost market share to generic rivals at a slower pace than the company's previous modelling had expected. The maker of drugs that treat opioid addiction posted a pretax profit of $89 million in the second quarter ended June 30 from $78 million a year earlier. Revenue fell nearly 20% to $215 million in the quarter due to the expected decline in market share for Suboxone, but Indivior reaffirmed that it expects 2019 revenue to be between $670 million and $720 million.

  • PR Newswire

    Indivior First Half 2019 Results Now Available; Conference Call With Leadership Today

    SLOUGH, England and RICHMOND, Va. , July 31, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that its first half 2019 results press release and investor supplement are now available via the ...

  • Reuters

    Indivior loses appeal to block generic Suboxone opioid treatments

    The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents. Suboxone film is applied below a patient's tongue, where it dissolves to release two active ingredients, buprenorphine and naloxone.

  • Reuters

    UPDATE 1-Indivior loses appeal to block generic Suboxone opioid treatments

    A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents. The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents.

  • Reckitt's Opioid Settlement Offers Some Relief
    Bloomberg

    Reckitt's Opioid Settlement Offers Some Relief

    (Bloomberg Opinion) -- Reckitt Benckiser Plc has taken the medicine.The company has settled with U.S. authorities to resolve a long-running investigation into the sale and marketing of an opioid addiction treatment by former subsidiary Indivior Plc.The payment is a big one: $1.4 billion. That far exceeds the $400 million provision it had set aside. But it draws a line under an issue that had threatened to derail a potential break-up of the maker of Cillit Bang cleaner and Durex condoms. Reckitt denied any wrongdoing, and said the settlement was in the best interests of the company and investors.It certainly isn’t helpful to the company’s balance sheet – it will increase net debt to 2.8 times Ebitda at the end of this year, according to Martin Deboo, analyst at Jefferies. That further constrains the company’s ability to participate in industry M&A. However, the shares rose about 3% on Thursday. This indicates the outcome was no worse than feared. Analysts at Bernstein had suggested back in April, when Indivior was indicted by the Justice Department, that the worst case scenario could be $1.5 billion.What’s more, the settlement does not bar Reckitt from participating in U.S. government programs, such as one that provides free baby milk. Losing this would have been extremely damaging to the infant nutrition business that Reckitt added when it acquired Mead Johnson.But even more important is that by resolving the issue, Reckitt can now move forward unencumbered. Outgoing chief executive Rakesh Kapoor deserves credit for finalizing the matter before his departure, leaving a clean slate to his successor, Laxman Narasimhan.The potential liabilities threatened to hamper the logical conclusion of Reckitt’s separation into two divisions, one focused on household products, and the other on consumer health.Narasimhan will still face significant challenges when he arrives shortly. Chief among them is reinvigorating sales growth, which stalled under his predecessor. He must also determine whether Reckitt's industry-leading margins can be sustained, or whether some profitability must be sacrificed to step up investment and turbo charge sales growth.But at least he can now pursue a break-up – assuming he wants to – without the U.S. legal risks hanging over him.To contact the author of this story: Andrea Felsted at afelsted@bloomberg.netTo contact the editor responsible for this story: Jennifer Ryan at jryan13@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Andrea Felsted is a Bloomberg Opinion columnist covering the consumer and retail industries. She previously worked at the Financial Times.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • PR Newswire

    Indivior Raises FY 2019 Net Revenue and Net Income Guidance; Cash at H1 2019 Expected to be Approximately $985m

    SLOUGH, England and RICHMOND, Va. , July 11, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced revised expectations for FY 2019 net revenue and net income following stronger than expected H1 ...

  • Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment probes
    Reuters

    Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment probes

    The settlement, the largest by any company related to the U.S. opioid epidemic, resolved long-running probes by the U.S. Justice Department and the Federal Trade Commission into the companies' marketing and sales of Suboxone Film. The deal came after Indivior in April was indicted and accused of deceiving doctors and healthcare benefit programs into believing Suboxone Film, itself a form of opioid, was safer and less susceptible to abuse than similar drugs.

  • Reuters

    UPDATE 2-Reckitt to pay $1.4 bln to end Indivior probe

    Britain's Reckitt Benckiser will pay up to $1.4 billion to resolve all U.S. federal investigations into the sales and marketing of an opioid addiction treatment by its former prescription pharmaceuticals business Indivior. Reckitt Benckiser (RB) said it had reached agreements with the U.S. Department of Justice (DOJ) and the Federal Trade Commission (FTC) to resolve the investigation into a business that was wholly demerged from the company in 2014. The U.S. Justice Department had accused Indivior of illegally boosting prescriptions for the opioid addiction treatment, called Suboxone Film.

  • GlobeNewswire

    DEADLINE MONDAY ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Indivior PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Indivior PLC (“Indivior” or “the Company”) (OTC: INVVY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Indivior and its executives participated in a scheme to increase prescriptions of Suboxone Film.

  • ACCESSWIRE

    FINAL DEADLINE ALERT - Indivior PLC (INVVY) Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: June 24, 2019

    NEW YORK, NY / ACCESSWIRE / June 24, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Indivior PLC ("Indivior" or the "Company") ...

  • GlobeNewswire

    CLASS ACTION UPDATE for INVVY, MBNKF, XENT and ZUO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, June 24, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..

  • GlobeNewswire

    INDIVIOR 24 HOUR DEADLINE ALERT: APPROXIMATELY 24 HOURS REMAIN; FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Indivior PLC - INVVY

    NEW ORLEANS, June 23, 2019 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large.

  • GlobeNewswire

    ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Reminds Indivior PLC Investors of Final Deadline on Monday in Securities Class Action Commenced by the Firm – INVVY

    NEW YORK, June 22, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Indivior PLC (OTC: INVVY) from March 10, 2015 through.